Literature DB >> 17785450

Skp2B stimulates mammary gland development by inhibiting REA, the repressor of the estrogen receptor.

Karina Umanskaya1, Susanne Radke, Harish Chander, Rosie Monardo, Xinsong Xu, Zhen-Qiang Pan, Matthew J O'Connell, Doris Germain.   

Abstract

Skp2B, an F-box protein of unknown function, is frequently overexpressed in breast cancer. In order to determine the function of Skp2B and whether it has a role in breast cancer, we performed a two-hybrid screen and established transgenic mice expressing Skp2B in the mammary glands. We found that Skp2B interacts with the repressor of estrogen receptor activity (REA) and that overexpression of Skp2B leads to a reduction in REA levels. In the mammary glands of MMTV-Skp2B mice, REA levels are also low. Our results show that in virgin transgenic females, Skp2B induces lobuloalveolar development and differentiation of the mammary glands normally observed during pregnancy. As this phenotype is identical to what was observed for REA heterozygote mice, our observations suggest that the Skp2B-REA interaction is physiologically relevant. However, in contrast to REA(+/-) mice, MMTV-Skp2B mice develop mammary tumors, suggesting that Skp2B affects additional proteins. These results indicate that the observed expression of Skp2B in breast cancer does contribute to tumorigenesis at least in part by modulating the activity of the estrogen receptor.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785450      PMCID: PMC2169057          DOI: 10.1128/MCB.01239-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  21 in total

1.  Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex.

Authors:  B A Schulman; A C Carrano; P D Jeffrey; Z Bowen; E R Kinnucan; M S Finnin; S J Elledge; J W Harper; M Pagano; N P Pavletich
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

Review 2.  Signaling pathways in mammary gland development.

Authors:  L Hennighausen; G W Robinson
Journal:  Dev Cell       Date:  2001-10       Impact factor: 12.270

3.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

4.  Haploinsufficiency of the corepressor of estrogen receptor activity (REA) enhances estrogen receptor function in the mammary gland.

Authors:  Paola Mussi; Lan Liao; Seong-Eun Park; Paolo Ciana; Adriana Maggi; Benita S Katzenellenbogen; Jianming Xu; Bert W O'Malley
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-25       Impact factor: 11.205

5.  A splice variant of Skp2 is retained in the cytoplasm and fails to direct cyclin D1 ubiquitination in the uterine cancer cell line SK-UT.

Authors:  S Ganiatsas; R Dow; A Thompson; B Schulman; D Germain
Journal:  Oncogene       Date:  2001-06-21       Impact factor: 9.867

6.  Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer.

Authors:  Sabina Signoretti; Lucia Di Marcotullio; Andrea Richardson; Sridhar Ramaswamy; Beth Isaac; Montserrat Rue; Franco Monti; Massimo Loda; Michele Pagano
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  A quantitative RT-PCR study of the mRNA expression profile of the IGF axis during mammary gland development.

Authors:  M Boutinaud; J H Shand; M A Park; K Phillips; J Beattie; D J Flint; G J Allan
Journal:  J Mol Endocrinol       Date:  2004-08       Impact factor: 5.098

8.  Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma.

Authors:  Andreja Pirkmaier; Renee Dow; Soula Ganiatsas; Paul Waring; Kerry Warren; Anne Thompson; Joy Hendley; Doris Germain
Journal:  Oncogene       Date:  2003-07-10       Impact factor: 9.867

9.  Expression of the insulin-like growth factor binding proteins during postnatal development of the murine mammary gland.

Authors:  Michael A Allar; Teresa L Wood
Journal:  Endocrinology       Date:  2004-01-28       Impact factor: 4.736

10.  Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.

Authors:  A Hengstermann; L K Linares; A Ciechanover; N J Whitaker; M Scheffner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-23       Impact factor: 11.205

View more
  11 in total

1.  Repressor of estrogen receptor activity (REA) is essential for mammary gland morphogenesis and functional activities: studies in conditional knockout mice.

Authors:  Sunghee Park; Yuechao Zhao; Sangyeon Yoon; Jianming Xu; Lan Liao; John Lydon; Franco DeMayo; Bert W O'Malley; Benita S Katzenellenbogen
Journal:  Endocrinology       Date:  2011-08-23       Impact factor: 4.736

Review 2.  Deregulation of F-box proteins and its consequence on cancer development, progression and metastasis.

Authors:  Jinho Heo; Rebeka Eki; Tarek Abbas
Journal:  Semin Cancer Biol       Date:  2015-09-30       Impact factor: 15.707

Review 3.  MicroRNA regulation of F-box proteins and its role in cancer.

Authors:  Zhao-Hui Wu; Lawrence M Pfeffer
Journal:  Semin Cancer Biol       Date:  2015-10-01       Impact factor: 15.707

4.  Skp2B attenuates p53 function by inhibiting prohibitin.

Authors:  Harish Chander; Max Halpern; Lois Resnick-Silverman; James J Manfredi; Doris Germain
Journal:  EMBO Rep       Date:  2010-02-05       Impact factor: 8.807

Review 5.  Roles of F-box proteins in cancer.

Authors:  Zhiwei Wang; Pengda Liu; Hiroyuki Inuzuka; Wenyi Wei
Journal:  Nat Rev Cancer       Date:  2014-04       Impact factor: 60.716

6.  Skp2 and Skp2B team up against Rb and p53.

Authors:  Doris Germain
Journal:  Cell Div       Date:  2011-01-21       Impact factor: 5.130

7.  Skp2B overexpression alters a prohibitin-p53 axis and the transcription of PAPP-A, the protease of insulin-like growth factor binding protein 4.

Authors:  Harish Chander; Max Halpern; Lois Resnick-Silverman; James J Manfredi; Doris Germain
Journal:  PLoS One       Date:  2011-08-04       Impact factor: 3.240

8.  Skp2 is a promising therapeutic target in breast cancer.

Authors:  Zhiwei Wang; Hidefumi Fukushima; Hiroyuki Inuzuka; Lixin Wan; Pengda Liu; Daming Gao; Fazlul H Sarkar; Wenyi Wei
Journal:  Front Oncol       Date:  2012-01-04       Impact factor: 6.244

9.  ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.

Authors:  Fabrice Sircoulomb; Nathalie Nicolas; Anthony Ferrari; Pascal Finetti; Ismahane Bekhouche; Estelle Rousselet; Aurélie Lonigro; José Adélaïde; Emilie Baudelet; Séverine Esteyriès; Julien Wicinski; Stéphane Audebert; Emmanuelle Charafe-Jauffret; Jocelyne Jacquemier; Marc Lopez; Jean-Paul Borg; Christos Sotiriou; Cornel Popovici; François Bertucci; Daniel Birnbaum; Max Chaffanet; Christophe Ginestier
Journal:  EMBO Mol Med       Date:  2011-02-15       Impact factor: 12.137

10.  Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.